# Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

> **NCT03676504** · PHASE1,PHASE2 · RECRUITING · sponsor: **University Hospital Heidelberg** · enrollment: 68 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia, Adult
- Acute Lymphoblastic Leukemia, Pediatric
- Chronic Lymphocytic Leukemia
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma

## Interventions

- **BIOLOGICAL:** CD19.CAR T Cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03676504
- **Lead sponsor:** University Hospital Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-09-07
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03676504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03676504, "Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03676504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*